Inhibition on LS-174T cell growth and activity of telomerase in vitro and in vivo by arsenic trioxide

Experimental and Toxicologic Pathology

Volumn 60, Issue 6, 2008, Pages 481-488

  Wang, Xishan ^a   Wang, Guiyu ^a   Dong, Deli ^a   Fu, Songbin ^a   Yang, Baofeng ^a  

^a HARBIN MEDICAL UNIVERSITY   (China)

Author keywords

Apoptosis; Arsenicals; Colorectal carcinoma; Telomerase inhibitor

Indexed keywords

ARSENIC TRIOXIDE; FLUOROURACIL; TELOMERASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER CELL; CELL GROWTH; COLORECTAL CARCINOMA; CONCENTRATION RESPONSE; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME LINKED IMMUNOSORBENT ASSAY; FLUORESCENCE ACTIVATED CELL SORTER; HETEROCHROMATIN; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; POLYMERASE CHAIN REACTION; TUMOR VOLUME; XENOGRAFT;

ADENOCARCINOMA; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; ARSENICALS; CELL LINE, TUMOR; CELL NUCLEUS; CELL SURVIVAL; COLORECTAL NEOPLASMS; CYTOPLASMIC STRUCTURES; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; FORMAZANS; HUMANS; MICE; MICE, NUDE; OXIDES; POLYMERASE CHAIN REACTION; TELOMERASE; TETRAZOLIUM SALTS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

MUS MUSCULUS;

EID: 49949106797     PISSN: 09402993     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.etp.2008.04.011     Document Type: Article

References (37)

1. Antman K.H. Introduction: the history of arsenic trioxide in cancer therapy. Oncologist 6 (2001) 1-2
2. Baj G., Arnulfo A., Deaglio S., Mallone R., Vigone A., De Cesaris M.G., et al. Arsenic trioxide and breast cancer: analysis of the apoptotic, differentiative and immunomodulatory effects. Breast Cancer Res Treat 73 (2002) 61-73
3. Baumgartner M., Sturlan S., Roth E., Wessner B., and Bachleitner-Hofmann T. Enhancement of arsenic trioxide-mediated apoptosis using docosahexaenoic acid in arsenic trioxide-resistant solid tumor cells. Int J Cancer 112 (2004) 707-712
4. Bornstein J., Sagi S., Haj A., Harroch J., and Fares F. Arsenic trioxide inhibits the growth of human ovarian carcinoma cell line. Gynecol Oncol 99 (2005) 726-729
5. Candoni A., Silvestri F., Buonamici S., Li D., Reddy P., Galili N., et al. Targeted therapies in myelodysplastic syndromes: ASH 2003 review. Semin Hematol 41 (2004) 13-20
6. 3 induces NB4 cell apoptosis with downregulation of Bcl-2 expression and modulation of PML-RAR alpha/PML proteins. Blood 88 (1996) 1052-1061
7. Chou W.C., Hawkins A.L., Barrett J.F., Griffin C.A., and Dang C.V. Arsenic inhibition of telomerase transcription leads to genetic instability. J Clin Invest 108 (2001) 1541-1547
8. Chou W.C., Chen H.Y., Yu S.L., Cheng L., Yang P.C., and Dang C.V. Arsenic suppresses gene expression in promyelocytic leukemia cells partly through Sp1 oxidation. Blood 106 (2005) 304-310
9. Counter C.M., Avilion A.A., LeFeuvre C.E., Stewart N.G., Greider C.W., Harley C.B., et al. Telomere shortening associated with chromosome instability is arrested in immortal cells which express telomerase activity. EMBO J 11 (1992) 1921-1929
10. Du C., Li D., Lin Y., and Wu M. Differentiation of human nasopharyngeal carcinoma xenografts and repression of telomerase activity induced by arsenic trioxide. Natl Med J India 17 (2004) 67-70
11. Evens A.M., Tallman M.S., and Gartenhaus R.B. The potential of arsenic trioxide in the treatment of malignant disease: past, present, and future. Leuk Res 28 (2004) 891-900
12. Fu W., Begley J.G., Killen M.W., and Mattson M.P. Anti-apoptotic role of telomerase in pheochromocytoma cells. J Biol Chem 274 (1999) 7264-7271
13. Fukai Y., Hirata M., Ueno M., Ichikawa N., Kobayashi H., Saitoh H., et al. Clinical pharmacokinetic study of arsenic trioxide in an acute promyelocytic leukemia (APL) patient: speciation of arsenic metabolites in serum and urine. Biol Pharm Bull 29 (2006) 1022-1027
14. Gartenhaus R.B., Prachand S.N., Paniaqua M., Li Y., and Gordon L.I. Arsenic trioxide cytotoxicity in steroid and chemotherapy-resistant myeloma cell lines: enhancement of apoptosis by manipulation of cellular redox state. Clin Cancer Res 8 (2002) 566-572
15. Hayakawa F., and Privalsky M.L. Phosphorylation of PML by mitogen-activated protein kinases plays a key role in arsenic trioxide-mediated apoptosis. Cancer Cell 5 (2004) 389-401
16. Jiang G., Bi K., Tang T., Zhang Y., Ren H., Jiang F., et al. Effect of arsenic trioxide on cytokine expression by acute promyelocytic leukemia cells. Chin Med J (Engl) 116 (2003) 1639-1643
17. Karlsson J., Ora I., Porn-Ares I., and Pahlman S. Arsenic trioxide-induced death of neuroblastoma cells involves activation of Bax and does not require p53. Clin Cancer Res 10 (2004) 3179-3188
18. Kim N.W., Piatyszek M.A., Prowse K.R., Harley C.B., West M.D., Ho P.L., et al. Specific association of human telomerase activity with immortal cells and cancer. Science 266 (1994) 2011-2015
19. Li M., and Gu J. Changing patterns of colorectal cancer in China over a period of 20 years. World J Gastroenterol 11 (2005) 4685-4688
20. Li X., Ding X., and Adrian T.E. Arsenic trioxide induces apoptosis in pancreatic cancer cells via changes in cell cycle, caspase activation, and GADD expression. Pancreas 27 (2003) 174-179
21. Li X., Ding X., and Adrian T.E. Arsenic trioxide causes redistribution of cell cycle, caspase activation, and GADD expression in human colonic, breast, and pancreatic cancer cells. Cancer Invest 22 (2004) 389-400
22. Miller Jr. W.H., Schipper H.M., Lee J.S., Singer J., and Waxman S. Mechanisms of action of arsenic trioxide. Cancer Res 62 (2002) 3893-3903
23. Soignet S.L. Clinical experience of arsenic trioxide in relapsed acute promyelocytic leukemia. Oncologist 6 (2001) 11-16
24. Sun Y., Kim S.H., Zhou D.C., Ding W., Paietta E., Guidez F., et al. Acute promyelocytic leukemia cell line AP-1060 established as a cytokine-dependent culture from a patient clinically resistant to all-trans retinoic acid and arsenic trioxide. Leukemia 18 (2004) 1258-1269
25. Tallmann M.S. Curative therapeutic approaches to APL. Ann Hematol 83 (2004) S81-S82
26. Wang H.Y., Liu S.X., and Zhang M. Gene expression profile changes in NB4 cells induced by arsenic trioxide. Acta Pharmacol Sin 24 (2003) 646-650
27. Wang S.S., Zhang T., Wang X.L., Hong L., and Qi Q.H. Effect of arsenic trioxide on rat hepatocellular carcinoma and its renal cytotoxicity. World J Gastroenterol 9 (2003) 930-935
28. Wang X.S., Wang K., Li X., and Fu S.B. Effects of phosphorothioate anti-sense oligodeoxynucleotides on colorectal cancer cell growth and telomerase activity. World J Gastroenterol 10 (2004) 3455-3458
29. Wei Y.M., Ou Y.X., Bai H., Lu J.H., and Zheng R.L. Down-regulation of four arsenic antagonists on apoptosis and telomerase activity induced by arsenic trioxide in three myelocytic leukemia cell lines. Acta Pharmacol Sin 22 (2001) 725-730
30. Xie D., Yin S., Ou Y., Bai H., Ding F., Wang X., et al. Arsenic trioxide (As(2)O(3)) induced apoptosis and its mechanisms in a human esophageal squamous carcinoma cell line. Chin Med J (Engl) 115 (2002) 280-285
31. Yu D., Wang Z., Zhu L., and Chew E.C. Nuclear matrix associated protein PML: an arsenic trioxide apoptosis therapeutic target protein in HepG2 cells. Chin Med J (Engl) 116 (2003) 93-98
32. Zhang T.C., Schmitt M.T., and Mumford J.L. Effects of arsenic on telomerase and telomeres in relation to cell proliferation and apoptosis in human keratinocytes and leukemia cells in vitro. Carcinogenesis 24 (2003) 1811-1817
33. Zhang Y., Cao E.H., Liang X.Q., and Qin J.F. Increasing sensitivity to arsenic trioxide-induced apoptosis by altered telomere state. Eur J Pharmacol 474 (2003) 141-147
34. Zhang Y., Cao E.H., and Qin J.F. Up-regulation of telomere-binding TRF1, TRF2 related to reactive oxygen species induced by As(2)O(3) in MGC-803 cells. Eur J Pharmacol 516 (2005) 1-9
35. Zheng J., Deng Y.P., Lin C., Fu M., Xiao P.G., and Wu M. Arsenic trioxide induces apoptosis of HPV16 DNA-immortalized human cervical epithelial cells and selectively inhibits viral gene expression. Int J Cancer 82 (1999) 286-292
36. Zhong L., Chen F., Han J., Shao N., and Ouyang R. Effects of red orpiment on cell morphology and expression of PML mRNA and protein in NB4 and HL-60 cells. Chin Med J (Engl) 116 (2003) 148-150
37. Zhou C., Boggess J.F., Bae-Jump V., and Gehrig P.A. Induction of apoptosis and inhibition of telomerase activity by arsenic trioxide (As(2)O(3)) in endometrial carcinoma cells. Gynecol Oncol (2007)